Proposes a dividend of Re 0.60 per share
Suven Life Sciences announced its audited financial results for the year ended March 31, 2015. The audited financial results were reviewed by the audit committee and approved by the Board of Directors in their recently held meeting at Hyderabad. For the year ended March 2015, the company posted a growth in revenue of Rs 5294 million. It has registered a growth in PAT of Rs 1088 million and growth in earnings before interest, taxes, depreciation, and amortisation (EBIDTA) of Rs 1680 million. For the fourth quarter ended March 2015, the company posted a revenue growth of Rs 1145 million, growth in PAT of Rs 169 million and growth in EBIDTA of Rs 265 million. The board has proposed a dividend of Res 0.60 per share (60 per cent of face value Rs 1 each) for the financial year 2014-15, subject to approval of the shareholders in the ensuing annual general meeting.
Comments are closed.